Non-alcoholic steatohepatitis (NASH) is characterized by chronic hepatic steatosis leading to inflammation and eventually fibrosis of the liver; it is commonly accepted as the hepatic manifestation of the metabolic syndrome. There are currently no disease-specific approved drug therapies for NASH in any of the major pharmaceutical markets, which creates a significant unmet need considering the large prevalent population and expectation that NASH will become the leading indication for liver transplant in the US in the next few years. 

Development of a safe and efficacious pharmacotherapy has been hindered by the complicated and poorly understood pathophysiology of NASH. Moreover, due to the multifactorial nature of the disease, more than one pharmacotherapy is likely to be required for effective treatment. Consequently, there is a diverse range of modes of action in the pipeline and substantial interest in combination therapies. 

This Datamonitor Healthcare report contains a Disease Analysis module.